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Abstract
RON belongs to the c-MET family of receptor tyrosine kinases. As its well-known family member MET, RON and its
ligand macrophage-stimulating protein have been implicated in the progression and metastasis of tumors and
have been shown to be overexpressed in cancer. We generated and tested a large number of human monoclonal
antibodies (mAbs) against human RON. Our screening yielded three high-affinity antibodies that efficiently block
ligand-dependent intracellular AKT and MAPK signaling. This effect correlates with the strong reduction of ligand-
activated migration of T47D breast cancer cell line. By cross-competition experiments, we showed that the an-
tagonistic antibodies fall into three distinct epitope regions of the RON extracellular Sema domain. Notably, no
inhibition of tumor growth was observed in different epithelial tumor xenografts in nude mice with any of the anti-
bodies. These results suggest that distinct properties beside ligand antagonism are required for anti-RON mAbs to
exert antitumor effects in vivo.
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Introduction
Monoclonal antibodies (mAbs) are attractive therapeutic drug candi-
dates in cancer therapy thanks to their potential for disease-specific
targeting and low-toxicity profiles. Significant progress has been
made in recent years in this field. However, there is substantial dif-
ficulty in predicting the efficacy of mAbs because the molecular path-
ways leading to their therapeutic effect are not clearly understood.
Although many mechanisms have been proposed to account for
the antitumor activities of therapeutic antibodies as a consequence
of the interference with signaling pathways, antibody-dependent cell
cytotoxicity stands also as a crucial component of the in vivo anti-
tumor effect exerted by antibodies targeting tumor antigens [1].
Receptor tyrosine kinases (RTKs) are preferred target candidates
for new mAbs because they fine-tune cellular pathways that control
events involved in cellular growth and migration that are important
in cancer development and progression.
The recepteur d’origine nantais (RON), also known as macrophage
stimulating 1 receptor, is a member of the MET proto-oncogene fam-
ily of RTKs and has been shown to be important in cancer [2–6]. It
is a 180-kDa disulfide-linked heterodimeric protein composed of a
35-kDa extracellular α-chain and a 150-kDa transmembrane β-chain
with intrinsic kinase activity and regulatory elements [2,7]. The extra-
cellular segment contains a Sema domain that constitutes the distinc-
tive structural and functional elements of semaphorins, their plexin
receptors, and the RTK MET [8–10]. This domain seems to pro-
vide a common structural scaffold that can be adopted to mediate a
diverse range of protein-protein interactions such as dimerization,
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semaphorin-plexin binding, and receptor-ligand binding. RON’s Sema
domain is considered to be the ligand-binding region [2,9,10].
RON is mainly expressed in epithelial cells and is highly expressed
and activated in most primary breast, colon, and pancreatic samples
and tumor cell lines [2,4,11–15]. Ligand of RON is the macrophage-
stimulating protein (MSP), which is a 78-kDa growth and motility
factor [12,16,17]. RON and its ligand MSP have been implicated in
the progression and metastasis of tumors. On binding to its ligand
MSP, RON becomes phosphorylated at key intracellular tyrosine
residues that provide docking sites for downstream signaling adapter
molecules and triggers activation of several signaling pathways that
include the Ras/MAPK, PI3K/Akt, and FAK pathways [18,19].
On stimulation with MSP, RON enhances invasion and cell motility
in various epithelial cell lines [13,20]. A recent study demonstrated
RON as a novel molecular target of hypoxia-inducible factor 1 and
suggested a potential therapeutic role for RON TK inhibitors in the
blockade of RON tyrosine kinase–mediated invasion of carcinoma
cells [21].
RON is in cross talk with other RTKs, cell surface proteins and
growth factors such as epidermal growth factor receptor (EGFR),
MET, integrins, and transforming growth factor β [22–26]. RON
activation can enhance signaling through c-MET and EGFR, both
associated with tumorigenesis [25,27]. The changes associated with
the epithelial-to-mesenchymal transition due to RON activation to-
gether with the ability of MSP-activated RON to increase cellular
migration further support a role for RON in metastasis [23]. Tissue-
specific overexpression of RON resulted in aggressive tumor formation
in transgenic mouse models of lung and breast cancer [28,29].
There is a body of evidence that suggest that RON should be
considered as target for cancer therapy [30]. Efforts to develop a can-
cer therapeutic specific for this RTK have generated a variety of
agents that block RON signaling and alter oncogenic phenotypes
[3,6,9,31]. Recently, a mAb, IMC-41A10, was reported to bind hu-
man RON with high affinity and to inhibit MSP binding as well as
MSP-mediated RON, MAPK, and AKT phosphorylation and MSP-
dependent in vitro cell migration. IMC-41A10 inhibited growth of
tumor xenografts in nude mice, and its antitumor efficacy was en-
hanced when administered in combination with Erbitux [12].
In this study, we have extensively characterized three mAbs against
RON, which were identified through the screening of a human scFv
phage displayed library. These novel mAbs bind with high affinity to
human RON, recognize distinct sites on the Sema domain, block
downstream signaling mediated by MSP binding, and inhibit MSP-
driven migration of T47D cells. Despite these characteristics being
similar to those of IMC-41A10, no in vivo efficacy was detected with
any of our antagonistic RON mAbs. Our results indicate that different
mechanism(s) other than ligand antagonism and inhibition of down-
stream signaling are needed for a RON mAb to have a therapeutic
potential in cancer.
Materials and Methods
Cell Lines
T47D, BxPC3, ZR-75, HT29, MDA-MB-231, DU145, SW480,
HPAC, HEK293, and 293-EBNA cells were purchased from ATCC
(Milan, Italy) and grown as recommended by the manufacturer ex-
cept T47D cells, which were grown in Dulbecco modified Eagle me-
dium F-12 Glutamax medium (GIBCO-Invitrogen, Carlsbad, CA),
enriched with 10% FBS at 37°C and 5% CO2.
To generate cell lines that overexpress Ron receptor, complementary
DNA (cDNA) encoding the full-length RON protein was cloned into
the Gateway-pcDNA-Dest40 expression vector (Invitrogen, Carlsbad,
CA) and into the doxycycline-inducible expression vector pCEP/
TetO-MCS. CHO cells were transfected with Gateway-pcDNA-
Dest40-RON construct, and HEK 293 cells were transfected with
pCEP/TetO-MCS-RON construct using Lipofectamine 2000 (Invi-
trogen) according to manufacturer’s protocol. Cells expressing high
RON levels were FACS-sorted and grown under appropriate antibiotic
selection to obtain stable clones (Geneticin for pDest 40 -RON,Hygro-
mycin for pCEP/TetO-MCS-RON).
Identification of Human Anti-RON ScFv Antibodies from
Phage Display Libraries
Human ScFv phage-display libraries with high complexity (>1011
different clones) were obtained from Cambridge Antibody Technol-
ogy Group plc (CaT). Each CAT library has undergone two rounds
of selection. The first round was carried out by panning the phage
library on recombinant RON SEMA-PSI domain (R&D Systems,
Minneapolis, MN) followed by a second-round selection with
SW480 cells naturally expressing RON. Phage rescue and amplifica-
tion were carried out between subsequent selections as described
[32]. After two rounds of selection, individual phage clones were ex-
amined by phage ELISA for their binding capability to immobilized
RON-Fc (Sigma-Aldrich, St Louis, MO) through the use of an anti-
Fc Ab (immunoPure Goat anti hIgG [Fc]; Pierce, Milan, Italy). Bound
phage was revealed with HRP-conjugated anti M1 monoclonal anti-
body (Amersham Biosciences, Milan, Italy) using tetramethylbenzidine
(Sigma-Aldrich) as substrate. Positive clones were converted from an
ScFv to an IgG1 format as previously described [33]. Positive clones
were also tested by phage ELISA for their binding to human recom-
binant MET-Fc (R&D Systems) and to the recombinant mouse RON
(R&D). The scFv VH and VL sequences were introduced into mam-
malian expression plasmids to produce IgG1 heavy or light chain using
the Gateway technology (Invitrogen, Carlsbad, CA). The two plasmids
were cotransfected into 293-EBNA cells using Lipofectamine (Invitro-
gen). Secreted IgG was purified from the medium by affinity chroma-
tography on a Protein A Sepharose High Performance prepacked
column (1 ml of HiTrap Protein A HP; GE Healthcare, Milan, Italy).
Identification of mAbs That Bind Selectively to RON Using
FACS Analysis
Each purified RON mAb was tested for its binding to RON-
positive cells (CHO/RON, HEK293/RON + doxycycline, SW480,
T47D, HCT116) or RON-negative cells (CHO wt, HEK293/
RON-doxycycline) using FACS analysis. MAbs were labeled by in-
cubation with Zenon Human IgG Alexa Fluor 488 Labeling Kit
(Molecular Probes/Invitrogen, Carlsbad, CA) according to the man-
ufacturer’s guidelines. Cells were then incubated with 50 μg/ml pre-
labeled mAb solution for 30 minutes at room temperature (RT; 2 ×
105 cells in 100 ml of phosphate-buffered saline (PBS), 2% BSA for
30 minutes), washed, and fixed with 1% paraformaldehyde in PBS.
Analysis was done using BD FACS Canto II cytometer and BD Diva
analysis software (BD Biosciences, Milan, Italy).
Immunoprecipitation/Mass Spectrometry
Experiment—Identification of Target Receptors
Experiments was carried out as before [34]. Shortly, immunoprecipi-
tation (IP) with RON IgGs 4, 7, and 10was carried out on fluorescently
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labeled (Cy5) membrane proteins. One-dimensional PAGE was fol-
lowed by in-gel digestion of immunoprecipitated protein bands and
identification of the protein bands using matrix-assisted laser desorption
ionization–time of flight–mass spectrometer (MALDI-TOF-MS). Data
were elaborated using the TurboSequest software (Thermo Electron
Rodano, Milan, Italy). Candidates with Xcorr values greater than 2.5
were considered identified with high confidence.
Kd Determination Through FACS Analysis
A total of 4 × 105 T47D cells were incubated with related RON
IgGs with increasing concentrations from 3.4 × 10−4 to 60 nM in
FACS buffer (0.2% BSA, 10 mM HEPES) for 1 hour at RT followed
by 40 minutes of incubation with APC/F(ab′)2 fragment goat anti-
human IgG Fcγ fragment specific ( Jackson ImmunoResearch, Milan,
Italy) at RT. Analysis was carried out using BD FACS Canto II cytom-
eter and BD Diva analysis software. K d values were determined using
Sigma Plot 10 software (Systat Software, San Jose, CA).
Cross-competition Assay
A total of 5 × 105 T47D cells per sample were washed once with
PBS 1% BSA and incubated with 100 μg/ml of competitor IgG or
unrelated human IgG (IgG1, Lambda, from human myeloma plasma;
Sigma) for 40 minutes at room temperature on an orbital shaker.
The IgG to be tested was labeled with AlexaFluor 647 using Zenon
AlexaFluor 647 for human IgG (cat. no. Z25408; Molecular Probes).
After a wash with PBS 1% BSA, cells saturated for the first IgG were
incubated with different concentrations of the labeled antibody (330,
66, 13, 2.6, 0.5, and 0 nM) for 40 minutes at RTon an orbital shaker.
After a wash with PBS 1% BSA, cells were fixed in 1% formaldehyde
in PBS. Analysis was done using BD FACS Canto II cytometer and
BD Diva analysis software. Binding curves were prepared using Sigma
Plot 10 software.
Western Blot Experiments
Induction with MSP. Subconfluent RON-expressing cell lines
(HT29, MDA-MB-231, Bx-Pc3, ZR-75, T47D, DU145, SW480,
and HPAC) were serum-starved for 18 hours. Wild-type MSP (10 nM;
R&D) was used to induce cells for 30 minutes at 37°C.
Testing RON IgGs’ ability to block MSP-driven induction. After
18 hours of serum starvation, 100 μg/ml of RON IgGs was incubated
with subconfluent BxPC3, T47D, and ZR-75 cell lines for 1 hour at
37°C before 30 minutes of induction with MSP. ID1 commercial
blocking antibody CD136 (RON; Beckman Coulter, Milan, Italy)
against RON was used as a positive control, and an unrelated antibody
(IgG1, Lambda, from human myeloma plasma; Sigma) was used as a
negative control.
RON IgGs dose-response experiment. Subconfluent T47D cells
that were serum-starved for 18 hours were incubated with increasing
concentrations of RON mAbs (2.4, 7.3, 22, and 66 nM) for 1 hour.
MSP, 10 nM, was used to induce T47D cells for 30 minutes at 37°C.
Time course experiment with RON mAbs. A total of 4.5 × 105
T47D cells per well in a six-well plate for each point were used. The
day after plating, cells were treated with 20 μg/ml of RON mAbs 4,
7, and 10 for 30 minutes, 1 hour, 4 hours, or 24 hours.
Cell lysate preparation and Western blot analysis. Cells were
lysed using lysis buffer (50 mM Tris, 1% Triton, 150 mM NaCl,
complete protease inhibitor cocktail (Roche, Milan, Italy), halt phos-
phatase inhibitor cocktail [Thermo Scientific, Milan, Italy]). Total
protein concentration was determined by Bradford method, 20 μg
of total protein per sample was loaded on 4% to 12% NuPage BisTris
Gels, and SDS-PAGE was performed. Proteins were transferred on to a
22-μm nitrocellulose membrane that was then blocked with 5% nonfat
dry milk in 0.05% Tween in TBS. For determination of extracellular
signal–regulated kinase (ERK) (mitogen-activated protein kinase,
MAPK) and AKT phosphorylation, p44/42 MAPK Thr202/Tyr204
rabbit mAb (1:1000; Cell Signaling, Milan, Italy) and phospho–Akt/
Ser473 (1:500; Cell Signaling) were used. Protein-blotted membranes
were incubated overnight at 4°C with primary antibodies in 5% BSA in
0.05% Tween in TBS. HRP-conjugated rabbit (Abcam, Cambridge,
UK) and mouse (Promega, Madison, WI) secondary antibodies were
used as 1:1500 and 1:3000, respectively, carrying out 1 hour of incuba-
tion at RT. To verify equivalent sample loading, blots were probed for
β-actin (NeoMarkers, Fremont, CA). Blots were developed using ECL
reagent (GE Healthcare, Milan, Italy). Images were acquired by lumi-
nescent image analyzer LAS3000 and then quantified by MultiGauge
version 2.2 software (FUJIfilm, Düsseldorf, Germany). To determine
expression levels of total ERK and total AKT, these membranes were
stripped with Restore Western Blot Stripping Buffer for 15 minutes at
room temperature (Pierce) and reprobed with p44/42 MAPK (1:1000;
Cell Signaling) or anti-AKT antibody (1:2000; Cell Signaling). After
washing and incubating with the secondary antibody, development
and image analysis were carried out as before. For determination of
RON protein levels, Ron (C-20) sc-322 rabbit polyclonal IgG and
HRP-conjugated rabbit (Abcam) were used.
Cell Migration Assay
Twenty-four–well HCTFluoroBlok Insert Systems with fluorescence
blocking PETmembranes were used as migration chambers (BD Bio-
sciences). T47D cells were serum starved for 18 hours and then plated
as 5 × 104 cells per well in serum-free medium on previously collagen
coated Fluoroblok chambers (rat tail collagen type I; BD Biosciences).
Recombinant hMSP C672A (R&D Systems) was added at a final con-
centration of 2 nM to the bottom chambers. (Recombinant MSP
C672A has increased bioactivity than recombinant MSP [35] because
of the limited incorrect disulfide bond formation, so the concentration
used in comparison to the previous experiments is lower than previously
made signaling experiments as we were furnished with MSP C672A
by R&D only during half of this study.) RON mAbs or an unrelated
human IgG (IgG1, Lambda, from human myeloma plasma; Sigma)
were added in both upper and lower chambers at a final concentration
of 20μg/ml before stimulation withMSP. After 2-nMMSPstimulation,
cells are allowed tomigrate for 24 hours at 37°C and 5%CO2.Migrated
cells were quantified after fluorescent labeling with 4μg/mlCalcein-AM
(Fluka, Milan, Italy) and by using fluorescence plate reader VICTOR2
(Perkin Elmer, Waltham, MA).
Cell Cytotoxicity Assay
T47D cells were serum-starved for 18 hours and were plated in
96-well plates that had been previously coated with collagen (rat tail
collagen type I; BD Biosciences) Ron mAbs or an unrelated human
IgG in combination with MSP (2-nM recombinant hMSP C672A;
R&D Systems) were added to the cells in serum-free medium. After
24 hours of incubation at 37°C and 5% CO2, ATP levels of cells
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were measured using ATPlite 1 step reagent (Perkin Elmer) using
Perkin Elmer TopCount microplate luminescence counter.
In Vivo Mouse Models
In the T47D model, 17β-estradiol pellets (0.36 mg per pellet,
60-day release) were implanted in the dorsal midline of 5-week-old
female NOD/SCID mice. After 1 week, 2 × 106 T47D cells in
Matrigel were injected in the fourth mammary fat pad. Nineteen days
after injection, mice with tumors greater than 30 mm3 were allocated
randomly in five groups. Mice were treated weekly with 25 mg/kg in-
traperitoneally with RON mAbs and isotypic control human IgG1.
On day 29 after allocation, mice were killed, and tumors were excised,
weighed, and frozen in liquid nitrogen.
In the following two in vivomodels, 5-week-old female athymic nude
mice (Charles River, Calco, Como, Italy) were injected subcutaneously
with 5 × 106 BxPC3 cells in Matrigel or intraperitoneally with HT29
cells in Matrigel. After tumors reached an average size of 150 to
200 mm3, 25-mg/kg intraperitoneal treatment with RON mAbs
or histidine buffer was carried out biweekly. At day 26 after treatment,
mice were killed, and tumors were excised, weighed, and frozen in
liquid nitrogen.
Results
Identification and Characterization of RON Specific mAbs
To identify RON-specific mAbs, we screened a human scFv phage-
displayed library obtained from CaTwith the following selection strat-
egy: a first round of selection was carried out on the recombinant
RON Sema-PSI domain, and the recovered phages were screened by
a second round of selection on SW480 cells that express high levels of
endogenous RON on the cell surface. Finally, individual scFv phages
specific for RON were screened for binding to the closely related fam-
ily member human recombinant MET-Fc and to the recombinant
mouse RON. The restricted pool of RON-specific phages was found
to bind selectively to human RON but not to mouse RON or human
MET (data not shown). Individual phage clones were converted into
a human type 1 IgGs and subjected to a further round of screening in
a whole-cell binding FACS assay using RON-positive and -negative
cell lines. IgG4, IgG7, and IgG10 were found to bind specifically to
CHO/RON when compared with CHO wt (Figure W1B). We fur-
ther confirmed the specificity of RON mAbs by IP of fluorescently
labeled membrane proteins with RON mAbs followed by in-gel diges-
tion of protein bands and peptide identification by MALDI-TOF-MS
mass spectrometry (IP-MS). All RON mAbs specifically immunopre-
cipitated two major bands in polyacrylamide gel, which were identified
as RON α and β chains (Figure W1A).
IgG4, IgG7, and IgG10 Bind RON with High Affinity
To determine the mAbs’ affinity toward RON receptor, we per-
formed whole-cell FACS binding assays on T47D cells endogenously
expressing RON. IgG4, IgG7, and IgG10 all displayed high affinity
toward RON (Figure 1) with subnanomolar K d values of 0.17, 0.43,
and 0.64 nM, respectively.
Antagonistic RON mAbs Bind to Different Epitopes on
Sema Domain
Because of the strategy used to select RON-specific antibodies, the
novel RON mAbs IgG4, IgG7, and IgG10 bound to the Sema do-
main of RON. To ensure that these mAbs recognized different regions
of the Sema domain, the epitope binding specificity was evaluated. A
FACS-based cross-competition experiment was performed in which
the binding of one tagged antibody to RON-displaying cells was mea-
sured in the presence of a potential competitor antibody or an unre-
lated IgG1 isotypic control at saturating concentration. As a reference,
the commercially available blocking mAb ID1 was also included. This
antibody is known to bind to the RON extracellular domain [36].
Notably, IgG4, IgG7, and IgG10 did not cross compete with each
other, as the extent of binding was not altered by the presence of
another mAb (Figure 2, A and B). Only mAb ID1 and IgG7 cross-
competed with each other, as IgG7 binding to RON was strongly in-
hibited in the presence of ID1 (Figure 2B). As shown by the simplified
cartoon in Figure 2C , these results indicate that IgG4, IgG7, and
IgG10 bind to different regions of the RON Sema domain, whereas
ID1 and 7 bind to the same or to closely positioned regions.
RON mAbs Block Downstream Signaling
Overexpression of the receptor as a consequence of transfection of
the RON cDNA often results in autophosphorylation of this RTK
regardless of MSP stimulation [37]. Therefore, to study the effect
of RON mAbs on ligand-dependent receptor signaling, different cell
Figure 1. IgG4, IgG7, and IgG10 bind RON with high affinity. Bind-
ing saturation curves determined by whole-cell FACS binding as-
say are represented as mean fluorescence intensities (MFIs) over
antibody concentration (nM). Calculated Kd values for IgG4, IgG7,
and IgG10 were 0.17, 0.43, and 0.64 nM, respectively.
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lines were used that endogenously express RON. In addition, to eval-
uate the ability of the RON mAbs to inhibit phosphorylation of ERK
and AKT, an extensive screening of tumor cell lines was carried out to
identify cells that expressed RON and at the same time showed ERK
and AKT phosphorylation on MSP binding. As shown in Figure 3A,
the pancreatic cancer cell line BxPC3 and the breast cancer cell lines
ZR-75 and T47D exhibited a strong MSP-dependent phosphoryla-
tion of AKT and ERK. Kinetics of the treatment of RON-expressing
cells with the ligand MSP showed that the maximum phosphoryla-
tion of ERK and AKT was reached after 30 minutes of incubation
(Figure W2). To measure the inhibitory potency of the different anti-
bodies, dose-response experiments were carried out in the T47D cells.
Increasing concentrations of IgG4, IgG7, and IgG10 or unrelated
IgG1 isotypic control were incubated with T47D cells before MSP
stimulation. All mAbs inhibited both ERK (Figure 2B) and AKT (data
not shown) phosphorylation in a dose-dependent manner. Because the
intensity of the pERK signal was stronger than pAKT, the half-maximal
inhibitory concentration (IC50) for each IgG was calculated on the basis
of the extent of pERK inhibition. The measured IC50 was 3 nM for
IgG4 and IgG10 and 50 nM for IgG7. Thus, these data demonstrate
that IgG4, IgG7, and IgG10 are high-affinity antibodies, specific for
human RON, which have ligand antagonistic activity. Finally, we inves-
tigated the cytotoxic potential of the antagonist RON mAbs 4, 7, and
10 in in vitro proliferation assays on T47D cells. Treatment with the
antibodies did not induce an antiproliferative effect, whereas a known
cytotoxic drug, cisplatin, clearly reduces proliferation (Figure W6).
Figure 2. RON IgGs bind to different regions of the Sema domain. (A) T47D cells were incubated with increasing concentrations of
labeled mAb4 in the presence of saturating amounts of mAb7, mAb10, or control isotypic IgG1 antibody (Ctrl IgG) as negative control.
(B) T47D cells were incubated with increasing concentrations of labeled mAb7 in the presence of saturating amounts of mAb10, ID1,
and control IgG. IgG4, IgG7, or IgG10 did not interfere with any other’s binding, indicating that they recognize different regions, whereas
ID1 blocks mAb7 binding, indicating that they recognize the same region. (C) Schematic cartoon summarizing the results of cross-
competition experiments.
Figure 3. RON IgGs block MSP-activated signaling. (A) Cell lysates of ZR75, T47D, and BxPC3 were assayed by Western blot analysis
with anti–phospho-Akt and anti–phospho-ERK antibodies. Antibodies directed to total Akt and total ERK were used as loading controls.
(B) Western blot analysis of cell lysates of T47D cells treated with increasing concentration of IgG4, IgG7, and IgG10 before MSP stim-
ulation. Signal intensities were quantified by densitometric scanning and expressed as chemiluminescence units. An antibody directed
to actin was used as a loading control.
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RON IgG4, IgG7, and IgG10 Inhibit MSP-Driven Migration
It has previously been shown that on stimulation with MSP, RON
enhances invasion and cell motility in various epithelial cell lines
[13,20,27]. To assess the effect of the selected mAbs on cell motil-
ity, a fluorimetric transwell migration assay was set up with T47D
cells where cells were allowed to migrate to the bottom chamber
for 24 hours through collagen-coated membranes in the presence
or absence of MSP. When the ligand was absent, a limited number
of cells spontaneously migrated to the bottom chamber after 24 hours
because of intrinsic cell motility. MSP stimulation caused up to a four-
fold increase in the extent of migration with respect to the unstim-
ulated condition. Migration of the cells to the bottom chamber was
equally inhibited by IgG4, IgG7, and IgG10 when the mAbs were
incubated with cells before MSP stimulation (Figure 4, A and C).
Because the three mAbs bind to the Sema domain, which is in-
volved in RON, cross talk with other membrane proteins and be-
cause they do not interfere with each other’s binding, we tested
the effect of antibodies when used in combination. Notably, when
IgG4, IgG7, and IgG10 were used in combination, they showed a
stronger inhibiting effect on T47D migration, which not only was
limited to inhibition of MSP-driven migration but also blocked the
spontaneous motility of T47D cells. A significant effect was observed
with IgG7-IgG10 or IgG4-IgG7 combinations, whereas IgG4-IgG10
exerted a lesser inhibitory effect. Nonetheless, all three combinations
were more efficient than ID1 alone (Figure 4C). These results suggest
that RON has a role in migratory machinery of T47D cells also inde-
pendently from MSP stimulation. To exclude the possibility that the
RON mAbs inhibitory effect on migration was due to receptor inter-
nalization, we carried out a time course experiment. T47D cells were
treated for 30 minutes, 1 hour, 4 hours, or 24 hours with RON mAbs,
and whole-cell lysates were evaluated for RON protein amount with
Western Blot. As clearly shown in Figure 4B, there was no reduction in
RON protein amounts during treatment with any of the RON mAbs.
To control that the strong inhibitory effect was not due to mAb’s in-
duced cytotoxicity, cell viability in the migration assay conditions was
measured in the presence of the mAbs either as single agents or in
combination. No effect on cell viability due to the presence of the anti-
bodies was observed (Figure W5). Thus, we concluded that the com-
binatorial effect of the RON mAbs was due to an enhanced block in
receptor signaling.
IgG4, IgG7, and IgG10 Do Not Display Antitumor Activity
In Vivo
We have generated an orthotopic mammary tumor xenograft model
with implanted T47D cells to study the efficacy of IgG4, IgG7, and
IgG10 in vivo. Groups of seven mice were randomly allocated at
Figure 4. RON IgGs significantly block MSP-driven migration. (A) Representative images of fluorescently labeled T47D migrated to the
lower side of the PET membrane in a Boyden chamber after 24 hours with or without MSP stimulation. (B) RON IgG4, IgG7, and IgG10
do not downregulate the RON receptor. T47D cells were treated with RON IgGs for 30 minutes, 1 hour, 4 hours, and 24 hours. (C)
Migration activity of T47D cells was measured by a 24-well HCT FluoroBlok assay and expressed as arbitrary units. MSP stimulation
(2 nM) caused up to a four-fold increase in migration with respect to untreated control. IgG4, IgG7, and IgG10 significantly blocked MSP-
driven migration (P = .001, P = .002, and P = .004, respectively) comparable to the commercially available mAb ID1. (D) Combination of
RON IgGs leads to an impairment of T47D spontaneous motility. Combination of IgG7-IgG10 and IgG4-IgG7 MSP inhibited spontaneous
motility of T47D cells by 75% to 80% (P = .02 and P = .01, respectively). Combination of IgG4-IgG10 also reduces the motility of T47D
although not significantly (P = .07). The experiments shown in the figures are representative of at least three different experiments.
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day 19 after inoculation based on mean tumor sizes of 150 to 200 mm3.
Mice were treated weekly with 25 mg/kg of RON mAbs or an isotypic
control IgG. On day 29 after treatment, the experiment was terminated.
The minor reduction observed was not statistically significant with
P values of .17 for IgG4, .23 for IgG7, and .23 for IgG10, with re-
spect to control IgG on day 29 (Figure 5).
To verify whether the lack of antitumor effect was not limited to a
single xenograft model, the selected IgGs were tested in mice injected
with BxPC3 or HT29 cell lines. Recent studies have shown that mAb
IMC-41A10 that blocks RON-mediated signaling also inhibits growth
of these tumor cell lines in vivo [12]. Groups of 10 mice were treated
with 25 mg/kg of the antibody. A control group was treated with his-
tidine buffer. Antibody treatment was initiated when the tumors were
85 to 130 mm3, and intraperitoneal injections were repeated twice
weekly during the study. Dosing schedule was established based on
preliminary mAb pharmacokinetic analyses in mice where the trough
level of the antibodies remained above the concentration needed for
receptor saturation in serum withdrawn 72 hours after mAb adminis-
tration (data not shown). In the BxPC3 xenograft, we could use an
antihuman IGF1R antibody as an internal positive control, which
has antitumor activity in this xenograft model. Unlike the reported
antitumor effects observed with mAb IMC-41A10, none of the antag-
onistic RON mAbs displayed an antitumor effect in either HT29 or
BxPC3 xenograft, whereas the positive control antihuman IGF1R
successfully inhibited tumor growth (Figures W3 and W4). The his-
topathology and the weight of the tumors from treated and untreated
mice were also not different.
Discussion
Although less extensively studied than the family member MET, accu-
mulating evidence suggest that RON RTK is important for cancer pro-
gression [2,3,12,14,38]. The pathways by which RON conveys signals
to the intracellular environment have been studied; however, the rela-
tionships of these different pathways to the specific biologic responses
that are relevant to tumor formation are still poorly defined [11].
RON and MET tyrosine kinase domains exhibit 63% sequence
identity [39]. Because of the high similarity with MET tyrosine ki-
nase domain, the development of potent and selective inhibitor drugs
targeting RON has so far been very challenging [3,40,41]. Biologic
drugs such as monoclonal antibodies or small interfering RNA (siRNA)
are therefore highly desirable for the high specificity for the target. Bio-
drugs that target the RON receptor are in the early stage of devel-
opment. The extracellular region of the RON receptor containing
the Sema domain was able to block the binding of MSP to RON
and to inhibit the growth of HCT116 colon cancer cells [9]. Silencing
using siRNA against RON reduced cancer cell proliferation and motil-
ity, increased apoptotic susceptibility of the cells in vitro, and signifi-
cantly reduced lung metastasis in vivo [31]. Neutralizing monoclonal
antibodies that block the interaction of RON with MSP and diminish
RON phosphorylation and downstream signaling have been developed
[12,36,40]. Nevertheless, so far, only one humanized antibody against
RON (IMC-41A10) has been found to significantly decrease tumor
growth of murine xenografts from subcutaneously injected lung, colon,
and pancreatic cancer cell lines in nude mice [12,42].
In this study, we describe the selection and characterization of
three fully human mAbs that are potent antagonists of the human
RON RTK. All three mAbs are highly specific for the human RON
receptor as shown by IP followed by mass spectrometry (IP-MS)
and highly selective; in fact, they do not cross react with mouse
RON nor recognize human MET. Moreover, they all show high affin-
ity binding to RON with measured Kd in the low-nanomolar range
(mAb4 = 0.17 nM, mAb7 = 0.43 nM, and mAb10 = 0.64 nM; Fig-
ure 1) and do not compete with each other for receptor binding, indi-
cating that they recognize different regions of the RON extracellular
domain (Figure 3).
AKT and ERK are key downstream effector molecules very impor-
tant in cancer progression and are also known to be modulated
through RON receptor signaling [3,12]. For this reason, we were
keen to evaluate whether the novel RON mAbs could inhibit AKT
and ERK phosphorylation and subsequent activation. Consistent
with their high affinity to RON, we found that IgG4, IgG7, and
IgG10 potently inhibited MSP-induced ERK phosphorylation in the
human mammary tumor cell line T47D in a dose-dependent man-
ner (Figure 2).
The effect of the selected IgGs on RON-mediated signaling was
assessed in transwell migration assays. All the three RON mAbs
strongly inhibited MSP-dependent migration of T47D cells, giving
a functional confirmation of their antagonistic activity (Figure 4).
Blocking different epitopes in a recognition site can modulate the
inhibitory effect on receptor-mediated signaling. Because our mAbs
bind to different epitopes, we hypothesized that, by occupying dif-
ferent sites present on the receptor, we might interfere with the in-
teraction of RON with other cell membrane elements and obtain a
greater antimigratory effect. Indeed, when cells were treated with a
combination of two mAbs, a significant reduction of T47D sponta-
neous motility was observed (Figure 5). Importantly, no effect on cell
viability was observed on treatment of the cells with the antibodies
alone or in combination. A recent work supporting the role of RON
in spontaneous cell motility showed that siRNA-mediated knock-
down of RON resulted in inhibition of ligand-independent motility
of human colon cancer cells [31]. Inhibition of the spontaneous mo-
tility by combinatorial treatment with Sema-binding mAbs might be
due to a more efficient blocking of the Sema domain leading to an
impairment of RON RTK interaction with different surface proteins
or receptors leading to reduction of spontaneous migration as well as
MSP-driven migration. This conclusion is supported by the observa-
tion that, in addition to its ligand, RON may be activated through
Figure 5. IgG4, IgG7, and IgG10 do not display antitumor efficacy
in orthotopic T47D xenograft. Groups of 10 mice were treated
weekly with 25 mg/kg of IgG starting when the mean tumor size
was between 150 and 200 mm3. The minor reduction observed
was not statistically significant with P values of .17 for IgG4, .23
for IgG7, and .23 for IgG10 with respect to control IgG on day 29.
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cross talk with other surface proteins such as MET, integrins, type B
plexins, and EGFR [22,25,26,43].
Because RON IgG4, IgG7, and IgG10 shared similar character-
istics but bound to distinct regions of the receptor, they were tested
in vivo to assess their antitumor potency. To this purpose, we estab-
lished different xenograft models used based on cell lines derived
from breast (T47D), colon (HT29), or pancreas (BxPC3) tumors.
Despite the potent inhibitory effect on RON signaling, none of the
mAbs had therapeutic efficacy in any of the three xenograft models.
This observation leads us to conclude that blocking MSP-dependent
signal transduction is not sufficient to inhibit tumor growth. There are
several possible explanations for this finding. In the first instance, it is
entirely possible that RON signaling in vivo is activated by the inter-
action with other membrane receptors. Previous studies had shown
that the physical interaction between RON and EGFR is ligand in-
dependent and that transphosphorylation of both receptors can be
induced on stimulation with either EGF or MSP [25,26]. Thus, for
an antitumor activity, not only antagonistic ability but also interfering
RON’s interaction with other surface proteins such as EGFR might
be needed. A second possibility is that the primary role of the RON
receptor in tumors might not be the activation of antiapoptotic path-
ways but rather the control of motility and migration. This hypothesis
cannot be easily ruled out in the xenograft models used in this study
where tumor growth at the primary site of inoculation is the main
parameter followed, but it could be better studied in mouse models
of metastasis formation. Indeed, we plan to test the efficacy of the
combinatorial administration of RON mAbs in metastatic models. Fi-
nally, it should be kept in mind that, for in vivo activity of therapeutic
mAbs, Fc receptor–dependentmechanisms such as antibody-dependent
cell-mediated cytotoxicity are important contributors [1]. We cannot
exclude that RON IgG4, IgG7, and IgG10 are not efficient in activat-
ing these mechanisms, which might render them less effective in vivo.
In conclusion, RON IgG4, IgG7, and IgG10, although being po-
tent antagonists of RON, do not seem to inhibit receptor-specific
signaling that may be relevant for tumor progression. These results
have important implications for future selection strategies of thera-
peutic mAbs for RON and, more in general, for RTK involved in
tumor development and progression, in that properties other than
blocking receptor signaling and inhibiting in vitro functions of RON
are needed to generate IgGs with in vivo antitumor activity.
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Figure W1. (A) RON IgGs are able to immunoprecipitate RON. Immunoprecipitation with RON IgG4, IgG7, and IgG10 was carried out on
fluorescently labeled membrane proteins. One-dimensional PAGE was followed by in-gel digestion of immunoprecipitated protein bands
and identification of the protein bands using MALDI-TOF-MS. Data were elaborated using the TurboSequest software. Candidates with
Xcorr values greater than 2.5 were considered identified with high confidence. (B) Whole-cell binding FACS analysis was carried out for
CHO wt or CHO-RON cells that are stably expressing RON full-length construct. IgG4, IgG7, and IgG10 specifically binds to CHO-RON
cells, whereas unrelated IgG used as control does not bind any of the cells as expected.
Figure W2. ZR-75 cells time course experiment for ERK and AKT
phosphorylation in response to MSP stimulation. The highest
phosphorylation levels were obtained at 30 minutes.
Figure W3. RON IgGs do not have antitumor activity in BxPC3
xenograft. Ten athymic nude mice per group were treated biweekly
with 25 mg/kg of IgG starting when the mean tumor size was be-
tween 150 and 200 mm3. An internal positive control MK1285, anti–
IGF-1R antibody, has antitumor activity in this model.
Figure W4. RON IgGs do not have antitumor activity in HT29
xenograft. Ten athymic nude mice per group were treated biweekly
with 25 mg/kg of IgG starting when the mean tumor size was be-
tween 150 and 200 mm3.
Figure W5. RON IgGs do not interfere with cell viability when used
alone or in combination. T47D cell viability was determined using
ViaLight Assay (Lonza, Milan, Italy), and values were expressed as
percentages relative to untreated control.
Figure W6. RON IgGs do not block T47D cell proliferation in vitro.
